ATE466027T1 - Abkömmlinge von glp-1 analogen - Google Patents
Abkömmlinge von glp-1 analogenInfo
- Publication number
- ATE466027T1 ATE466027T1 AT99906076T AT99906076T ATE466027T1 AT E466027 T1 ATE466027 T1 AT E466027T1 AT 99906076 T AT99906076 T AT 99906076T AT 99906076 T AT99906076 T AT 99906076T AT E466027 T1 ATE466027 T1 AT E466027T1
- Authority
- AT
- Austria
- Prior art keywords
- glp
- derivatives
- analogue
- analogs
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Dowels (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK26898 | 1998-02-27 | ||
PCT/DK1999/000082 WO1999043706A1 (en) | 1998-02-27 | 1999-02-25 | Derivatives of glp-1 analogs |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE466027T1 true ATE466027T1 (de) | 2010-05-15 |
Family
ID=8091634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99906076T ATE466027T1 (de) | 1998-02-27 | 1999-02-25 | Abkömmlinge von glp-1 analogen |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1060191B1 (de) |
JP (1) | JP2002512175A (de) |
AT (1) | ATE466027T1 (de) |
AU (1) | AU2610699A (de) |
DE (1) | DE69942306D1 (de) |
WO (1) | WO1999043706A1 (de) |
ZA (2) | ZA991570B (de) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002523333A (ja) | 1998-07-31 | 2002-07-30 | ノボ ノルディスク アクティーゼルスカブ | Ii型糖尿病を予防するためのglp−1及び類似体の利用 |
EP1263458B1 (de) | 2000-03-08 | 2005-11-16 | Novo Nordisk A/S | Senkung des serum cholesterols |
ATE424413T1 (de) | 2000-06-16 | 2009-03-15 | Lilly Co Eli | Analoge des glucagon-ähnlichen peptids-1 |
ATE416784T1 (de) | 2000-12-01 | 2008-12-15 | Takeda Pharmaceutical | Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz |
ES2311560T3 (es) * | 2000-12-07 | 2009-02-16 | Eli Lilly And Company | Proteinas de fusion glp-1. |
EP1949908A1 (de) | 2001-03-07 | 2008-07-30 | Novo Nordisk A/S | Kombinierter Einsatz von Derivaten von GLP-1-Analoga und PPAR-Liganden |
ES2298378T3 (es) | 2001-06-28 | 2008-05-16 | Novo Nordisk A/S | Formulacion estable de glp-1 modificado. |
KR100593348B1 (ko) | 2001-08-23 | 2006-06-26 | 일라이 릴리 앤드 캄파니 | 글루카곤-유사 펩티드-1 유사체 |
CA2452044A1 (en) * | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
JP2005508360A (ja) * | 2001-10-19 | 2005-03-31 | イーライ・リリー・アンド・カンパニー | Glp−1およびインスリンの二相混合物 |
PT1463751E (pt) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
AU2002364587A1 (en) | 2001-12-21 | 2003-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2003059378A2 (en) | 2001-12-29 | 2003-07-24 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
TW200306202A (en) * | 2002-01-08 | 2003-11-16 | Lilly Co Eli | Extended glucagon-like peptide-1 analogs |
MXPA04008068A (es) | 2002-02-20 | 2004-11-26 | Lilly Co Eli | Metodo para administrar moleculas de glp-1. |
AU2003272970B2 (en) | 2002-10-11 | 2009-05-28 | Sanwa Kagaku Kenkyusho Co. Ltd. | GLP-1 derivatives and transmicosal absorption preparations thereof |
EP1592471B1 (de) | 2003-02-04 | 2011-03-23 | Novo Nordisk A/S | Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung |
CA2513307A1 (en) * | 2003-02-19 | 2004-09-02 | Zheng Xin Dong | Analogues of glp-1 |
MXPA05009940A (es) * | 2003-03-19 | 2005-12-05 | Lilly Co Eli | Compuestos de glp-1 de enlace de glicol polietilenico. |
CN102174102A (zh) | 2003-05-15 | 2011-09-07 | 塔夫茨大学信托人 | 肽和多肽药物的稳定类似物 |
CN1812808B (zh) | 2003-06-03 | 2012-07-04 | 诺沃挪第克公司 | 稳定化的药物肽组合物 |
ES2380437T3 (es) | 2003-06-03 | 2012-05-11 | Novo Nordisk A/S | Composiciones farmacéuticas de péptido GLP-1 estabilizadas |
JP2007524592A (ja) | 2003-06-03 | 2007-08-30 | ノボ・ノルデイスク・エー/エス | 安定化された薬学的ペプチド組成物 |
US20060287221A1 (en) | 2003-11-13 | 2006-12-21 | Novo Nordisk A/S | Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia |
RU2421238C2 (ru) | 2003-11-20 | 2011-06-20 | Ново Нордиск А/С | Пептидная композиция, содержащая пропиленгликоль, являющаяся оптимальной для изготовления и применения в инъекционных устройствах |
EP1694356B1 (de) | 2003-12-09 | 2011-02-16 | Novo Nordisk A/S | Regulierung der nahrungspräferenz mit glp-1-agonisten |
EP1711523B1 (de) * | 2003-12-16 | 2012-10-10 | Ipsen Pharma | Glp-1-analoga |
ATE461217T1 (de) | 2003-12-18 | 2010-04-15 | Novo Nordisk As | Glp-1-verbindungen |
MXPA06007667A (es) | 2004-01-06 | 2006-09-01 | Novo Nordisk As | Heteroaril-ureas y su uso como activadores de glucocinasa. |
JP2007537149A (ja) | 2004-01-08 | 2007-12-20 | セラテクノロジーズ インコーポレイテッド | 長時間作用性のグルカゴン様ペプチド−1類似体 |
RU2385879C2 (ru) | 2004-01-21 | 2010-04-10 | Ново Нордиск Хелс Кеа Аг | Способ конъюгации пептидов, опосредованной трансглутаминазой |
PL1729795T3 (pl) | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Białka fuzyjne albuminy |
EP1758575A1 (de) | 2004-06-11 | 2007-03-07 | Novo Nordisk A/S | Bekämpfung von arzneimittel-induzierter fettleibigkeit unter verwendung von glp-1-agonisten |
WO2006024631A2 (en) | 2004-08-31 | 2006-03-09 | Novo Nordisk A/S | Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins |
US7893017B2 (en) | 2004-10-07 | 2011-02-22 | Novo Nordisk A/S | Protracted GLP-1 compounds |
EP2330126B1 (de) | 2004-10-07 | 2015-12-23 | Novo Nordisk A/S | Exendin-4-Zusammensetzungen mit verlängerter Halbwertszeit |
AU2005303777B2 (en) | 2004-11-12 | 2010-12-16 | Novo Nordisk A/S | Stable formulations of insulinotropic peptides |
JP2008521864A (ja) | 2004-12-03 | 2008-06-26 | トランステック・ファーマ、インコーポレイテッド | ヘテロ芳香族グルコキナーゼ活性化剤 |
EP1904467B1 (de) | 2005-07-14 | 2013-05-01 | Novo Nordisk A/S | Harnstoff-Glucokinase-Aktivatoren |
US20090054305A1 (en) | 2006-03-15 | 2009-02-26 | Novo Nordisk A/S | Mixtures of Amylin and Insulin |
US8318778B2 (en) | 2007-01-11 | 2012-11-27 | Novo Nordisk A/S | Urea glucokinase activators |
CN101743252A (zh) | 2007-07-16 | 2010-06-16 | 诺沃-诺迪斯克有限公司 | 蛋白酶稳定化的、peg化的胰岛素类似物 |
JP5241849B2 (ja) | 2007-11-16 | 2013-07-17 | ノボ・ノルデイスク・エー/エス | インスリン及びインスリン分泌性ペプチドを含む薬学的組成物 |
PT2254906T (pt) | 2008-03-18 | 2017-01-03 | Novo Nordisk As | Análogos de insulina acilados, estabilizados contra proteases |
US8889618B2 (en) | 2008-11-07 | 2014-11-18 | The General Hospital Corporation | C-terminal fragments of glucagon-like peptide-1 (GLP-1) |
EP2495255A4 (de) | 2009-10-30 | 2013-05-15 | Otsuka Chemical Co Ltd | Glycosylierte form eines antigenen glp-1-analogs |
WO2011073328A1 (en) * | 2009-12-16 | 2011-06-23 | Novo Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
EP2555791B1 (de) | 2010-04-09 | 2017-11-01 | Sinai Health System | Verfahren zur behandlung von erkrankungen des magen-darm-trakts mittels eines glp-1-agonisten |
US20130123460A1 (en) | 2010-04-30 | 2013-05-16 | Sanwa Kagaku Kenkyusho Co., Ltd. | Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability |
WO2012061466A2 (en) | 2010-11-02 | 2012-05-10 | The General Hospital Corporation | Methods for treating steatotic disease |
ES2683372T3 (es) * | 2010-11-09 | 2018-09-26 | Novo Nordisk A/S | Derivados de GLP-1 acilados con un conector nuevo |
PL2651398T3 (pl) | 2010-12-16 | 2018-05-30 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego |
CN103619175B (zh) * | 2011-04-12 | 2016-08-17 | 诺沃—诺迪斯克有限公司 | 双酰化glp-1衍生物 |
ES2712945T3 (es) * | 2011-04-12 | 2019-05-16 | Novo Nordisk As | Derivados de GLP-1 doblemente acilados |
WO2013006692A2 (en) | 2011-07-06 | 2013-01-10 | The General Hospital Corporation | Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) |
ES2626013T3 (es) * | 2011-09-06 | 2017-07-21 | Novo Nordisk A/S | Derivados de GLP-1 |
EP2788027A2 (de) | 2011-12-09 | 2014-10-15 | Novo Nordisk A/S | Glp-1-agonisten |
JP6356660B2 (ja) | 2012-03-22 | 2018-07-11 | ノヴォ ノルディスク アー/エス | 送達剤を含む組成物およびその調製 |
TR201903918T4 (tr) | 2012-03-22 | 2019-04-22 | Novo Nordisk As | Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması. |
HRP20231060T1 (hr) | 2012-03-22 | 2023-12-22 | Novo Nordisk A/S | Pripravci peptida glp-1 i njihova priprava |
EP2846824B1 (de) | 2012-05-08 | 2017-04-05 | Novo Nordisk A/S | Zweifach acylierte glp-1-derivate |
US10000542B2 (en) | 2012-05-08 | 2018-06-19 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
CN104487056A (zh) | 2012-06-20 | 2015-04-01 | 诺和诺德A/S(股份有限公司) | 包含肽和递送剂的片剂制剂 |
JP6224586B2 (ja) | 2012-07-10 | 2017-11-01 | 武田薬品工業株式会社 | 注射用製剤 |
EP2908844A1 (de) | 2012-10-17 | 2015-08-26 | Novo Nordisk A/S | Fettsäureacylierte aminosäuren zur oralen peptidfreisetzung |
BR112015030948A2 (pt) | 2013-06-20 | 2017-09-19 | Novo Nordisk As | Derivados de glp-1 e usos dos mesmos |
MX2015016875A (es) * | 2013-07-04 | 2016-04-07 | Novo Nordisk As | Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos. |
EP3129041B1 (de) | 2014-04-07 | 2019-06-12 | Novo Nordisk A/S | Zweifach acylierte glp-1-verbindungen |
EP3006045B3 (de) | 2014-10-07 | 2021-03-17 | Cyprumed GmbH | Pharmazeutische Formulierungen zur oralen Verabreichung von Peptid- oder Proteinarzneimitteln |
US11572398B2 (en) | 2014-11-27 | 2023-02-07 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
CN107108714B (zh) | 2014-12-17 | 2022-02-08 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
EP3359181A1 (de) | 2015-10-07 | 2018-08-15 | Cyprumed GmbH | Pharmazeutische formulierungen zur oralen verabreichung von peptidarzneimitteln |
WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
CN110545838A (zh) * | 2017-03-08 | 2019-12-06 | 因塔西亚制药公司 | 用于从药物递送装置施用致恶心化合物的设备和方法 |
PE20211202A1 (es) | 2017-08-24 | 2021-07-05 | Novo Nordisk As | Composiciones de glp-1 y sus usos |
EP3746111B1 (de) | 2018-02-02 | 2023-07-19 | Novo Nordisk A/S | Feste zusammensetzungen mit einem glp-1-agonisten, einem salz aus n-(8-(2-hydroxybenzoyl)amino)caprylsäure und einem schmierstoff |
EP3774862B1 (de) | 2018-04-05 | 2022-06-08 | Sun Pharmaceutical Industries Limited | Neuartige glp-1-analoga |
EP3773475A1 (de) | 2018-04-06 | 2021-02-17 | Cyprumed GmbH | Pharmazeutische zusammensetzungen zur transmukosalen abgabe von therapeutischen peptiden und proteinen |
TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
EP3938037A1 (de) | 2019-03-15 | 2022-01-19 | Diet4Life ApS | Kombination von diätetischen peptiden |
WO2021144476A1 (en) | 2020-02-18 | 2021-07-22 | Novo Nordisk A/S | Pharmaceutical formulations |
JP2023524695A (ja) | 2020-04-29 | 2023-06-13 | ノヴォ ノルディスク アー/エス | Glp-1作動薬およびヒスチジンを含む固形組成物 |
US20240041983A1 (en) | 2020-09-07 | 2024-02-08 | Cyprumed Gmbh | Improved pharmaceutical formulations of glp-1 receptor agonists |
CN115925994B (zh) | 2020-09-30 | 2023-09-22 | 北京质肽生物医药科技有限公司 | 多肽缀合物和使用方法 |
WO2022096636A1 (en) * | 2020-11-06 | 2022-05-12 | Novo Nordisk A/S | Glp-1 prodrugs and uses hereof |
CA3206148A1 (en) | 2021-01-24 | 2022-07-28 | Michael David FORREST | Therapeutic modifiers of the reverse mode of atp synthase |
EP4281039A2 (de) | 2021-01-25 | 2023-11-29 | Mylan Ireland Limited | Pharmazeutische glp-peptid-zusammensetzungen und verfahren zu ihrer herstellung |
WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
ATE110083T1 (de) | 1986-05-05 | 1994-09-15 | Gen Hospital Corp | Insulinotropes hormon. |
NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
DE68929217T2 (de) | 1989-03-20 | 2000-11-30 | Gen Hospital Corp | Insulinotropes hormon |
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
DK36392D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
DK36492D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Praeparat |
GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5869602A (en) * | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
CA2468374C (en) | 1996-08-30 | 2010-12-21 | Novo-Nordisk A/S | Glp-1 derivatives |
-
1999
- 1999-02-25 EP EP99906076A patent/EP1060191B1/de not_active Expired - Lifetime
- 1999-02-25 JP JP2000533456A patent/JP2002512175A/ja not_active Withdrawn
- 1999-02-25 AT AT99906076T patent/ATE466027T1/de not_active IP Right Cessation
- 1999-02-25 AU AU26106/99A patent/AU2610699A/en not_active Abandoned
- 1999-02-25 WO PCT/DK1999/000082 patent/WO1999043706A1/en active Application Filing
- 1999-02-25 DE DE69942306T patent/DE69942306D1/de not_active Expired - Lifetime
- 1999-02-26 ZA ZA9901570A patent/ZA991570B/xx unknown
- 1999-02-26 ZA ZA9901569A patent/ZA991569B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ZA991570B (en) | 1999-09-02 |
EP1060191A1 (de) | 2000-12-20 |
JP2002512175A (ja) | 2002-04-23 |
AU2610699A (en) | 1999-09-15 |
DE69942306D1 (de) | 2010-06-10 |
WO1999043706A1 (en) | 1999-09-02 |
ZA991569B (en) | 1999-08-27 |
EP1060191B1 (de) | 2010-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE466027T1 (de) | Abkömmlinge von glp-1 analogen | |
HUP9903714A2 (hu) | GLP-1-származékok | |
ATE192649T1 (de) | Stereochemische wortmanninderivate | |
TR199701146T1 (xx) | N�rotensin resept�rleri �zerinde etkili 1-Fenilpirazol-3-Karboksamidler. | |
HN1998000036A (es) | Compuesto de pirazina | |
NL1002835A1 (nl) | Synergistisch stabilisatormengsel. | |
DE60009511D1 (de) | Nematizide trifluorbutene | |
ES2186300T3 (es) | Oligopeptidos con actividad fungicida. | |
DE69941116D1 (de) | G von gdf-8 | |
TR200000782T2 (tr) | Resorsinol türevleri. | |
HRP20010117B1 (en) | Novel salt form of pantoprazole | |
DE69202164D1 (de) | Stabilisierung von Thiolenzusammensetzungen. | |
ES2183340T3 (es) | Procedimiento para la preparcion de compuestos de 4-bromometil-bifenilo. | |
SE9901077D0 (sv) | Novel use | |
SE9801494D0 (sv) | Novel use | |
FI950842A (fi) | Enkefalinaasin inhibiittoreina käyttökelpoisia uusia 2-substituoituja trisyklisiä indaani-2-merkaptoasetyyliamidijohdannaisia | |
DE60008353D1 (de) | Hemihydrat von 16.alpha.-bromoepiandrosterone | |
DK1250337T3 (da) | Substituerede homopiperidinylbenzimidazol-analoger som fundus-relaksanter | |
FI930265A0 (fi) | Antikoagulantpeptider | |
TR200003203T2 (tr) | Karboksaldehitin saflaştırılması | |
DE59808166D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure als mukolytikum | |
DK0633723T3 (da) | Anvendelse af iodbrintesyre som et afrodisiakum | |
ES2089281T3 (es) | Nuevos derivados de 2-mercaptometileno-tetrahidronaftaleno y 2-carboxamida indanos como inhibidores de la encefalinasa. | |
ES2178111T3 (es) | Uso de un compuesto 2-aroil-3-arilbenzo(b)tiofeno para rebajar los niveles de fibrinogeno. | |
NO913659L (no) | Hemming av hiv ved anvendelse av synergistiske kombinasjoner av nukleosidderivater. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |